Published on in CHOP News
CHOP researchers show convalescent plasma appears to be a safe and possibly effective treatment for children with life-threatening cases of COVID-19.
Learn how Kim Smith-Whitley, MD, is fighting to improve the lives of her patients in the wake of COVID-19.
Read morePublished on in CHOP News
New treatment developed by CHOP researchers poised to improve sepsis outcomes.
Published on in CHOP in the Media
The US Food and Drug Administration has granted accelerated approval to two novel drugs to treat sickle cell disease.
The US Food and Drug Administration has approved two new breakthrough therapies for patients with sickle cell disease (SCD), and we believe both may enhance the treatment of our patients here at CHOP.
Read morePublished on in CHOP News
Stefano Rivella, PhD, an expert in creating the next-generation lentiviral vectors for the cure of hemoglobinopathies including sickle cell disease (SCD), as well as a leader in the discovery of erythroid and iron disorders including beta-thalassemia, has led three new published studies that make significant contributions to the scientific body of literature regarding red blood cells, and how manipulating the production of red cells can lead to the development of new disease-modifying therapies.
Published on in CHOP News
Dr. Oved brings deep expertise to the group, having completed scientific and clinical training that included tenures as a Fulbright Fellow with the Weizmann Institute in Israel, the NYU School of Medicine with two years as a Howard Hughes Medical Fellow, followed by a residency in Pediatrics at NYP Weill Cornell Medical College.
Published on in CHOP News
Dr. George was recognized for the first gene therapy clinical trial to report a cure of hemophilia B patients.
Published on in Children's Doctor
Using the case of a 24-month-old African-American boy, Drs. Ganetzky and Goldstein discuss sideroblastic anemia and how it might be an indicator for multisystem mitochondrial disease.
Published on in CHOP News
Dr. Kurre will lead a world-renowned, multidisciplinary team in developing new therapies for BMF syndromes and in basic research.